Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Biphenotypic, Acute 1Down Syndrome 1Burkitt Lymphoma 1

Interventions

Cytarabine 4Mitoxantrone 2Cyclophosphamide 2vosaroxin 1thymoglobulin 1plerixafor 1fludarabine phosphate 1fludarabine 1devimistat 1aldesleukin 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Sorafenib 1Rituximab 1Mycophenolic Acid 1Melphalan 1Leyk 1Interleukin-2 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Daunorubicin 1Clofarabine 1Busulfan 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Myeloid × Leyk × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡